Invasive mycoses in organ transplant recipients: Controversies in prophylaxis and management

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 6, 2000, Pages 749-755

  Singh, Nina ^a,b  

^a VA Healthcare VISN 4   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ECHINOCANDIN B; FLUCONAZOLE; ITRACONAZOLE;

ASPERGILLOSIS; CANDIDIASIS; HUMAN; IMMUNOMODULATION; MYCOSIS; ORGAN TRANSPLANTATION; PROPHYLAXIS; REVIEW;

EID: 0034090029     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.6.749     Document Type: Review

References (64)

1. Kanj, S. S., Welty-Wolf, K., Madden, J., Tapson, V., Baz, M. A., Davis, R. D. et al. (1996). Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine 75, 142-56.
2. Paterson, D. L. & Singh, N. (1999). Invasive aspergillosis in transplant recipients. Medicine 78, 123-38.
3. Briegel, J., Forst, H., Spill, B., Haas, A., Grabein, B., Haller, M. et al. (1995). Risk factors for systemic fungal infections in liver transplant recipients. European Journal of Clinical Microbiology and Infectious Diseases 14, 375-82.
4. Paya, C. V. (1993). Fungal infections in solid-organ transplantation. Clinical Infectious Diseases 16, 677-88.
5. Singh, N., Chang, F. Y., Gayowski, T. & Marino, I. R. (1997). Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Clinical Infectious Diseases 24, 369-74.
6. Fortun, J., Lopez-San Roman, A., Velasco, J. J., Sanchez-Sousa, A., de Vincente, E., Nuno, J. et al. (1997). Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. European Journal of Clinical Microbiology and Infectious Diseases 16, 314-8.
7. Wong-Beringer, A., Jacobs, R. A. & Guglielmo, B. J. (1998). Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clinical Infectious Diseases 27, 603-18.
8. Roilides, E., Sein, T., Holmes, A., Chanock, S., Blake, C., Pizzo, P. A. et al. (1995). Effects of macrophage colony-stimulating factor on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. Journal of Infectious Diseases 172, 1028-34.
9. Stevens, D. A. (1998). Combination immunotherapy and antifungal chemotherapy. Clinical Infectious Diseases 26, 1266-9.
10. Nagai, H., Guo, J., Choi, H. & Kurup, V. (1995). Interferon-γ and tumor necrosis factor-α protect mice from invasive aspergillosis. Journal of Infectious Diseases 172, 1554-60.
11. Nadeem, I., Yeldandi, V., Sheridan, P., McCabe, M. A., Husain, A., Montoya, A. et al. (1997). Efficacy of itraconazole prophylaxis for aspergillosis in lung transplant recipients. In Program and Abstracts of the Thirty-Second Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, 1997. Abstract P58A. Infectious Diseases Society of America, Alexandria, VA.
12. Munoz, P., Palomo, J., Yanez, J., Alcala, L., Pelaez, T. et al. (1999). Primary prophylaxis with itraconazole of invasive aspergillosis (IA) in heart transplant (HT) patients. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 1416, p. 566. American Society for Microbiology, Washington, DC.
13. Stevens, D. A. (1999). Itraconazole in cyclodextrin solution. Pharmacotherapy 19, 603-11.
14. Colby, W. D., Sharpe, M. D., Ghent, C. N., Grant, D. R., Hunte, L., McDougall, J. et al. (1999). Efficacy of itraconazole prophylaxis against systemic fungal infection in liver transplant recipients. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 1650, p. 576. American Society for Microbiology, Washington, DC.
15. Menichetti, F., Del Favero, A., Martino, P., Bucaneve, G., Micozzi, A., Girmenia, C. et al. (1999). Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. Clinical Infectious Diseases 28, 250-5.
16. Morgenstern, G. R., Prentice, A. G., Prentice, H. G., Ropner, J. E., Schey, S. A. & Warnock, D. W. (1999). A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. British Journal of Haematology 105, 901-11.
17. Perfect, J. R., Klotman, M. E., Gilbert, C. C., Crawford, D. D., Rosner, G. L. & Wright, K. A. (1992). Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. Journal of Infectious Diseases 165, 891-7.
18. Riley, D. K., Pavia, A. T., Beatty, P. G., Petersen, F. B., Spruance, J. L., Stokes, R. et al. (1994). The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. American Journal of Medicine 97, 509-14.
19. Singh, N., Mieles, L., Yu, V. L. & Gayowski.T. (1993). Invasive aspergillosis in liver transplant recipients: association with candidemia and consumption coagulopathy and failure of prophylaxis with low-dose amphotericin B. Clinical Infectious Diseases 17, 906-8.
20. Braun, F., Ruchel, R., Lorf, T., Canelo, R., Muller, A., Sattler, B. et al. (1998). Is liposomal amphotericin B (ambisome) an effective prophylaxis of mycotic infections after liver transplantation? Transplantation Proceedings 30, 1481-3.
21. Tollemar, J., Hockerstedt, K., Ericzon, B. G., Jalanko, H. & Ringden, O. (1995). Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled trial. Transplantation 59, 45-50.
22. Varo, E., Tome, S., Bustamante, M., Martinez, J., Paredes, J., Conde, R. et al. (1998). Fungal infection prophylaxis in high-risk liver transplant recipients. In Program and Abstracts of the Thirty-Ninth International Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J-138, p. 490. American Society for Microbiology, Washington, DC.
23. Reichenspurner, H., Gamberg, P., Nitschke, M., Valentine, H., Hunt, S., Oyer, P. E. et al. (1997). Significant reduction in the number of fungal infections after lung, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplantation Proceedings 29, 627-8.
24. Trigg, M. E., Morgan, D., Burns, T. L., Kook, H., Rumelhart, S. L., Holida, M. D. et al. (1997). Successful program to prevent Aspergillus infections in children undergoing marrow transplantation: use of nasal amphotericin. Bone Marrow Transplantation 19, 43-7.
25. Guillemain, R., Lavarde, V., Amrein, C., Chevalier, P., Guinvarc'h, A. & Glotz, D. (1995). Invasive aspergillosis after transplantation. Transplantation Proceedings 27, 1307-9.
26. Jeffery, G. M., Beard, M. E., Ikram, R. B., Chua, J., Allen, J. R., Heaton, D. C. et al. (1991). Intranasal amhotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. American Journal of Medicine 90, 685-92.
27. Levine, M. S., Shpiner, R. B., Waters, P. F. & Kubak, B. M. (1995). Analysis of antifungal prophylaxis in lung transplantation. American Journal of Respiratory and Critical Care Medicine 151, A460.
28. Todeschini, G., Murari, G. C., Bonest, R., Pizzolo, G., Amaddi, G., Ambrosetti, A. et al. (1993). Oral itraconazole plus nasal amphotericin B for prophylaxis of invasive aspergillosis in patients with hematological malignancies. European Journal of Clinical Microbiology and Infectious Diseases 12, 614-8.
29. Behre, G. F., Schwartz, S., Lenz, K., Ludwig, W. D., Wandt, H., Schilling, E. et al. (1995). Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Annals of Hematology 71, 287-91.
30. Cicogna, C. E., White, M. H., Bernard, E. M., Ishimura, T., Sun, M., Tong, W. P. et al. (1997). Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 41, 259-61.
31. Palmer, S. M., Whitehouse, J., Drew, R. H., McConnell, R. R., Davis, R. D., Perfect, J. R. et al. (1998). Nebulized amphotericin B lipid complex prophylaxis is associated with a low rate of invasive fungal infections after lung transplantation. In Program and Abstracts of the American Thoracic Society International Conference, 1998. Abstract B42, p. 1054. American Thoracic Society, New York.
32. Severens, J. L., Donnelly, J. P., Meis, J. F., De Vries Robbe, P. F., De Pauw, B. E. & Verweij, P. E. (1997). Two strategies for managing invasive aspergillosis: a decision analysis. Clinical Infectious Diseases 25, 1148-54.
33. Abi-Said, D., Anaissie, E., Uzun, O., Raad, I., Pinzcowski, H. & Vartivarian, S. (1997). The epidemiology of hematogenous candidiasis caused by different Candida species. Clinical Infectious Diseases 24, 1122-8.
34. Nguyen, M. H., Peacock, J. E., Jr, Morris, A. J., Tanner, D. C., Nguyen, M. L., Snydman, D. R. et al. (1996). The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. American Journal of Medicine 100, 617-23.
35. Gleason, T. G., May, A. K., Caparelli, D., Farr, B. M. & Sawyer, R. G. (1997). Emerging evidence of selection of fluconazole-tolerant fungi in surgical intensive care units. Archives of Surgery 132, 1197-202.
36. van Burik, J. H., Leisenring, W., Myerson, D., Hackman, R. C., Shulman, H. M., Sale, G. E. et al. (1998). The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine 77, 246-54.
37. Winston, D. J., Pakrasi, A. & Busuttil, R. W. (1999). Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 131, 729-37.
38. Singh, N., Gayowski, T., Wagener, M. M., Doyle, H. & Marino, I. R. (1997). Invasive fungal infections in liver transplant recipients receiving tacrolimus as primary immunosuppressive agent. Clinical Infectious Diseases 24, 179-84.
39. Patel, R., Portela, D., Bradley, A. D., Harmsen, W. S., Larson-Keller, J. J., Ilstrup, D. M. et al. (1996). Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 62, 926-34.
40. Lumbreras, C., Cuervas-Mons, V., Jara, P., del Palacio, A., Turrion, V. S., Barrios, C. et al. (1996). Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. Journal of Infectious Diseases 174, 583-8.
41. Wingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Walshe, L. et al. (1999). Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clinical Infectious Diseases 29, 1402-7.
42. Gayowsksi, T., Marino, I. R., Singh, N., Doyle, H., Wagener, M., Fung, J. J. et al. (1998). Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 65, 499-504.
43. Leenders, A. C. A. P., de Marie, S., Ten Kate, M. T., Bakker-Woudenberg, I. A. J. M. & Verbrugh, H. A. (1996). Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy 38, 215-25.
44. White, M. H., Anaissie, E. J., Kusne, S., Wingard, J. R., Hiemenz, J. W., Cantor, A. et al. (1997). Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis. Clinical Infectious Diseases 24, 635-42.
45. Dixon, D. M., Walsh, T. J., Merz, W. G. & McGinnis, M. R. (1989). Infections due to Xylohypha bantiana (Cladosporium trichoides). Reviews of Infectious Diseases 11, 515-25.
46. Linden, P., Coley, K., Kramer, D., Kusne, S. & Fung, J. (1999). Invasive aspergillosis in liver transplant recipients: comparison of outcome with amphotericin B lipid-complex and conventional amphotericin B therapy. Transplantation 67, S232.
47. Williams, P., Waskin, H., Bolcsak, L. & Swenson, C. (1999). Amphotericin B concentrations in autopsy tissues of organ transplant patients administered amphotericin B lipid complex injection. Transplantation 67, S93.
48. Roilides, E., Lyman, C. A., Sein, T., Petraitis, V. & Walsh, T. (1999). Amphotericin B lipid complex synergized with pulmonary alveolar macrophages to destroy conidia of Aspergillus fumigatus. In Program and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999. Abstract 700, p. 555. American Society for Microbiology, Washington, DC.
49. Denning, D. W. (1997). Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. Journal of Antimicrobial Chemotherapy 40, 611-4.
50. Kurtz, M. B., Bernard, E. M., Edwards, F. F., Marrinan, J. A., Dropinski, J., Douglas, C. M. et al. (1995). Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 39, 1784-9.
51. Paterson, D. & Singh, N. (1999). Pulmonary mycoses in solid-organ transplant recipients. In Fungal Infections of the Lung, (Sarosi, G. A. & Davies, S. F., Eds), pp. 239-269. Williams & Wilkins, Baltimore, MD.
52. Singh, N., Gayowski, T. & Marino, I. R. (1998). Successful treatment of disseminated cyrptococcosis in a liver transplant recipient with fluconazole and 5 flucytosine, an all oral regimen. Transplant International 11, 63-5.
53. Singh, N., Chang, F. Y., Gayowski, T. & Marino, I. R. (1997). Infections due to dematiaceous fungi in organ transplant recipients: case report and review. Clinical Infectious Diseases 24, 369-74.
54. Caillot, D., Casasnovas, O., Bernard, A., Couaillier, J. F., Durand, C., Cuisenier, B. et al. (1997). Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. Journal of Clinical Oncology 15, 139-47.
55. Robinson, L. A., Reed, E. C., Galbraith, T. A., Alonso, A., Moulton, A. L. & Fleming, W. H. (1995). Pulmonary resection for invasive Aspergillus infections in immunocompromised patients. Journal of Thoracic and Cardiovascular Surgery 109, 1182-97.
56. Singh, N., Gayowski, T., Singh, J. & Yu, V. L. (1995). Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients. Clinical Infectious Diseases 20, 617-20.
57. Clancy, C. J. & Singh, N. (1998). Dematiaceous fungi: chromoblastomycosis, mycetoma, subcutaneous and cutaneous phaeohyphomycosis, and non-invasive sinusitis. In Antimicrobial Therapy and Vaccines, (Yu, V. L., Merigan, T. C. & Barriere, S. L., Eds), pp. 1095. Williams & Wilkins, Baltimore, MD.
58. Roilides, E., Uhlig, K., Venzon, D., Pizzo, P. A. & Walsh, T. J. (1993). Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infection and Immunity 61, 4870-7.
59. Catalano, L., Fontana, R., Scarpato, N., Picardi, M., Rocco, S. & Rotoli, B. (1997). Combined treatment with amphotericin B and granulocyte transfusion from G-CSF-stimulated donors in an aplastic patient with invasive aspergillosis undergoing bone marrow transplantation. Haematologica 82, 71-2.
60. Nemunaitis, J., Meyers, J. D., Buckner, C. D., Shannon-Dorcy, K., Mori, M., Shulman, H. et al. (1991). Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections. Blood 78, 907-13.
61. Graybill, J., Loebenberg, R., Bocanegra, R. & Najvar, L. (1998). Granulocyte colony stimulating factor (G-CSF) and azole antifungal therapy in murine aspergillosis: surprises. In Program and Abstracts of the Thirty-Eighth International Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract J-48, p. 464, American Society for Microbiology, Washington, DC.
62. The International Chronic Granulomatous Disease Cooperative Study Group. (1991). A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New England Journal of Medicine 324, 509-16.
63. Roilides, E., Holmes, A., Blake, C., Venzon, D., Pizzo, P. A. & Walsh, T. J. (1994). Antifungal activity of elutriated human monocytes against Aspergillus fumigatus hyphae: enhancement by granulocyte-macrophage colony-stimulating factor and interferon-gamma. Journal of Infectious Diseases 170, 894-9.
64. Halme, M., Maasilta, P., Repo, H., Ristola, M., Taskinen, E., Mattson, K. et al. (1995). Inhaled recombinant interferon gamma in patients with lung cancer; pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and monocytes. International Journal of Radiation Oncology, Biology, Physics 31, 93-101.